Title	Selective eradication of pluripotent stem cells by inhibiting DHODH activity
Author(s)	Kondo, Toru
Citation	Stem cells, 39(1), 33-42 https://doi.org/10.1002/stem.3290
Issue Date	2021-01
Doc URL	http://hdl.handle.net/2115/82146
Rights	Kondo, T. Selective eradication of pluripotent stem cells by inhibiting DHODH activity. Stem Cells. 2021; 39: 33–42. https://doi.org/10.1002/stem.3290 . © 2020 AlphaMed Press
Type	article (author version)
File Information	SC-20-0166.R1_Proof_hi.pdf

[Instructions for use](#)

Selective eradication of pluripotent stem cells by inhibiting DHODH activity

Toru Kondo^a

^aDivision of Stem Cell Biology, Institute for Genetic Medicine, Hokkaido University,
Sapporo, Hokkaido 060-0815, Japan

Correspondence: Toru Kondo, Ph.D.

Division of Stem Cell Biology, Institute for Genetic Medicine, Hokkaido University,
Kita-15, Nishi-7, Kita-ku, Sapporo, Hokkaido 060-0815, Japan
Tel: +81-11-706-6082, Fax: +81-11-706-7870, E-mail: tkondo@igm.hokudai.ac.jp

Running head: Selective elimination of PSCs by BRQ

Author contributions: Toru Kondo: conception and design, financial support,
collection and assembly of data, data analysis and interpretation, manuscript writing,
final approval of manuscript.

Key words: pluripotent stem cells (PSCs), dihydroorotate dehydrogenase (DHODH),
brequinar (BRQ), teratoma, regenerative medicine, cell therapy

Abstract

Pluripotent stem cells (PSCs), such as embryonic stem cells and induced pluripotent
stem cells, give rise to all kinds of functional cells, making them promising for

successful application in regenerative medicine. However, there is concern that a PSC-derived differentiated cell population may form teratomas when used for cell therapy if the population contains undifferentiated PSCs. Therefore, for the success of regenerative medicine, it is crucial to establish methods that induce complete PSC differentiation and eliminate the contamination of PSCs. Here, I show that the dihydroorotate dehydrogenase (DHODH) inhibitor brequinar (BRQ) induced cell cycle arrest, cell death, and stemness loss in PSCs, whereas it was less toxic against normal tissue-specific stem cells and differentiating cells. I demonstrate that BRQ-pretreated PSCs did not form teratomas after being transplanted into NOD/SCID mice. Moreover, BRQ administration to teratoma-bearing mice prevented tumour growth and decreased PSC marker levels in the tumour without any visible effects in the differentiated germ layer cells and the mice. Collectively, these data indicated that DHODH inhibitors such as BRQ can be indispensable in the fundamental methods of PSC-based therapy.

Significance statement

For the success of regenerative medicine, it is crucial to establish methods that exclude the contamination of PSCs in the differentiated cell population. The results of this study show that BRQ, the strongest available inhibitor of DHODH, specifically targets PSCs, whereas it is less cytotoxic towards lineage-committed progenitor cells and differentiated functional cells. Furthermore, BRQ prevents teratoma formation in vivo without any visible side effects in mice. These findings identify DHODH inhibitors, such as BRQ, as fundamental reagents for PSC-based cell therapy.

Introduction

1
2
3
4
5 Pluripotent stem cells (PSCs), such as embryonic stem cells (ESCs) and induced
6 pluripotent stem cells (iPSCs), proliferate indefinitely and give rise to all three
7 functional germ layer cells, including neurons, muscle cells, and blood cells; therefore,
8 PSCs have been extensively investigated for their characteristics and potential use in
9 regenerative medicine.¹⁻⁵ However, since undifferentiated PSCs form tumours called
10 teratomas, which can contain all three germ layer cells when transplanted in vivo, the
11 development of methods that induce complete cell differentiation, eliminate the
12 contamination of PSCs, and/or prevent teratoma formation after therapy is crucial for
13 the success of regenerative medicine.
14
15
16
17
18
19
20
21
22
23
24
25

26 Many strategies have been developed to eliminate the contamination of PSCs
27 from differentiated cultures by targeting PSC-specific characteristics, including the cell
28 surface membrane protein SSEA5, methionine depletion, and alkaline phosphatase
29 activity.⁶⁻⁸ Using high-throughput chemical screening, Ben-David et al. identified new
30 compounds that selectively kill PSCs.⁹ Although these strategies eliminate
31 undifferentiated PSCs in culture, these methods, **except the method shown by Ben-**
32 **David et al.,** have not been shown to eradicate the propagation of teratomas after cell
33 transplantation.
34
35
36
37
38
39
40
41
42
43

44 It has been demonstrated that PSCs and cancer cells produce ATP mainly by
45 glycolysis, while most somatic cells utilize oxidative phosphorylation to generate
46 energy.^{10,11} The use of glycolysis is an advantage for PSCs because glycolysis does not
47 generate harmful reactive oxygen species, which damage genomic and mitochondrial
48 DNA and oxidize both proteins and lipids, but rather produces nucleotides and lipids,
49 which support rapid PSC proliferation. Glutamine has been shown to be another major
50
51
52
53
54
55
56
57
58
59
60

carbon source for the proliferation of both PSCs and cancer cells.^{12,13} These findings indicate that PSCs and cancer cells utilize the same metabolic pathways to proliferate.

There is increasing evidence that dihydroorotate dehydrogenase (DHODH), an essential enzyme for the de novo pyrimidine synthesis pathway, is an attractive therapeutic target for many types of cancer, including melanoma, acute myeloid leukaemia, breast cancer, pancreatic cancer, and glioblastoma.¹⁴⁻¹⁸ DHODH inhibitors not only induce cell cycle arrest or cell death in cancer cells but also abolish stemness by preventing the O-GlcNAcylation of stem cell factors, such as Sox2 and Oct4. Given that glutamine is the substrate for the de novo pyrimidine synthesis pathway, these results suggest that DHODH inhibitors can be used to eliminate undifferentiated PSCs that persist throughout the differentiation-induction process. I show here that the DHODH inhibitor brequinar (BRQ) eliminated undifferentiated PSCs but was less toxic to normal cells, such as neural stem cells (NSCs), astrocytes, and myoblasts, in culture. BRQ also induced nuclear export of the PSC factors Oct4 and Nanog in a chromosomal maintenance 1 (Crm1)-dependent manner. Moreover, administration of BRQ prevented PSC tumorigenesis in vivo without inducing any visible side effects in mice. Collectively, these data indicate that DHODH inhibitors can be used in an essential basic technique of PSC therapy.

Materials and methods

Animals and chemical reagents

All experiments with mice were performed according to protocols approved by the Animal Care and Use Committees of Hokkaido University. The mice were obtained from Hokudo, Inc. (Sapporo, Japan, www.hokudo.co.jp), and chemicals and growth factors were purchased from Invitrogen (Carlsbad, CA, www.lifetechnologies.com/nl/en/home/brands/invitrogen.html) and PeproTech (Rocky Hill, NJ, www.peprotech.com), respectively, unless otherwise indicated.

Cell culture

Mouse ESCs (E14tg2a, gift from Dr. Masui) and iPSCs (iPS-Hep-FB/Ng/gfp-103C-1, RIKEN BRCs, Tsukuba, Japan) were maintained on gelatine- or iMatix 511 (Takara Bio Inc, Shiga, Japan, www.takara.co.jp)-coated culture plates in Glasgow MEM (GMEM, Sigma-Aldrich, St. Louis, MO, www.sigmaaldrich.com) supplemented with chemicals, sodium pyruvate (1 mM), 1x nonessential amino acids, 2-mercaptoethanol (0.1 mM, Nacalai Tesque, Kyoto, Japan), Leukemia inhibitory factor (LIF, ESGRO, 1000 units/ml, Merck Millipore, Darmstadt, Germany, www.merckmillipore.com), KnockOut Serum Replacement (KSR, 15%, Thermo Fisher Scientific, Grand Island, New York), foetal calf serum (FCS, 1%, HyClone), penicillin, and streptomycin (Nacalai Tesque, Kyoto, Japan) (PSC medium).

ESCs were transfected with pEGFP-N1 (Clontech, Takara Bio Inc, Shiga, Japan, www.takara.co.jp) using Lipofectamine 3000 (Thermo Fisher Scientific, Grand Island, New York) according to the manufacturer's protocol and then selected in the

presence of G418 (300 µg/ml, Nacalai Tesque, Kyoto, Japan), establishing EGFP-expressing ESCs (GFP⁺ ESCs).

NSCs were prepared from an embryonic day 17.5 mouse telencephalon and cultured as a monolayer on poly-D-lysine (PDL, 15 µg/ml)- and fibronectin (1 µg/ml, Invitrogen)-coated culture dishes in DMEM/F12 (Sigma-Aldrich, St. Louis, MO, www.sigmaaldrich.com) supplemented with chemicals, bFGF (10 ng/ml), and EGF (10 ng/ml) (NSC medium), as described previously.¹⁹ Astrocyte differentiation was induced by culturing NSCs in DMEM (Nacalai Tesque, Kyoto, Japan) containing FCS (10%), penicillin, and streptomycin (FCS medium) for three weeks, as described previously.²⁰ For cytotoxicity assays, PSCs were cultured on gelatine-coated 96-well plates in PSC medium, while NSCs and astrocytes were cultured on PDL- and fibronectin-coated 96-well plates in NSC and FCS media, respectively.

C2C12 myoblasts (gift from Dr. Sabe) and the PA6 stromal cell line (RIKEN BRC, Tsukuba, Japan)²¹ were cultured in DMEM and αMEM (Nacalai Tesque, Kyoto, Japan), respectively, both of which were supplemented with FCS (10%), penicillin, and streptomycin.

To examine cell cycle arrest, the MTT assay and BrdU incorporation assay were performed as described previously.^{22,23}

To analyse cytotoxicity, annexin V immunostaining was performed using the ApoScreen Annexin V-FITC Apoptosis Kit (Beckman Coulter, Brea, CA).

Additionally, GFP-expressing PSCs (5×10^5 cells) were co-cultured with NSCs (3×10^5 cells), which were labelled using PKH26 Red Fluorescent Cell Linker Kits (Sigma-Aldrich, St. Louis, MO, www.sigmaaldrich.com), in the presence or absence of BRQ (10 µM). Three days after incubation, cells were harvested using accutase (Nacalai

Tesque, Kyoto, Japan) and suspended in 10 ml of PBS. One microliter of the cell suspension was mixed with 9 μ l of trypan blue (Nacalai Tesque, Kyoto, Japan) and then, GFP⁺ and PKH26⁺ cells were quantified using an AxioImager M1 microscope (Carl Zeiss, Oberkochen, Germany). The kits were used according to the manufacturer's protocol.

PSC-derived NSC differentiation

NSC differentiation from mouse PSCs was induced using RHB-A medium (Takara Bio Inc, Shiga, Japan, www.takara.co.jp) according to the supplier's instructions. In brief, mouse PSCs were cultured in RHB-A medium alone for 5 days on iMatrix 511-coated culture plates. The medium was replaced with RHB-A medium containing bFGF (10 ng/ml) and EGF (10 ng/ml) on day 6 and with NSC medium on day 12. On day 15, the cells were harvested and cultured as a monolayer on PDL- and fibronectin-coated culture dishes in NSC medium. The medium was changed every 2-3 days. To induce neural differentiation, the cells were cultured in 8-well chambers in mitogen-free NSC medium or DMEM+1% FCS for 1 week (Supporting information Fig. 8A, 8B).

PSCs were co-cultured with PSC-NSCs in the presence or absence of BRQ (1 or 10 μ M) for 3 days, and then, Nanog⁺ and Nestin⁺ cells were quantified using an AxioImager M1 microscope (Carl Zeiss, Oberkochen, Germany).

Quantitative reverse-transcription polymerase chain reaction

Total RNA was extracted from cells using the RNeasy kit (Qiagen, Hilden, Germany, <http://www1.qiagen.com>) and reverse-transcribed using the Transcriptor First Strand cDNA Synthesis Kit (Roche Applied Science, Basel, Switzerland, <http://www.roche->

applied-science.com) according to the supplier’s instructions. Real-time polymerase chain reaction (PCR) was performed on a StepOnePlus instrument (Thermo Fisher Scientific, Grand Island, New York) using THUNDERBIRD SYBR qPCR Mix (Toyobo, Tokyo, Japan) according to the manufacturer’s protocol. The cycle parameters were as follows: 15 s at 95°C and 30 s at 60°C for 40 cycles. All gene expression data were normalized to the housekeeping gene 18S ribosomal RNA according to the $\Delta\Delta C_t$ method. The oligonucleotide primer sequences were as follows: mouse *sox2*, forward 5’-TGAAGAAGGATAAGTACACGCT-3’ and reverse 5’-TCCTGCATCATGCTGTAGCTG-3’; mouse *oct4*, forward 5’-CTGAAGCAGAAGAGGATCACC-3’ and reverse 5’-CCGCAGCTTACACATGTTCTT-3’; mouse *nanog*, forward 5’-CTGATTCTTCTACCAGTCCCAA-3’ and reverse 5’-AGAGTTCTTGCATCTGCTGGA-3’; and *18S*, forward 5’-CGGACAGGATTGACAGATTG-3’, and reverse 5’-CAAATCGCTCCACCAACTAA-3’.

Immunocytochemistry

Tumours were sectioned at a thickness of 10 µm and immunostained as described previously.^{24,25} The following antibodies were used for immunostaining: rabbit polyclonal anti-Sox2 (1:500, StemCell Technology, Vancouver, BC, Canada, <http://www.stemcell.com>), mouse monoclonal anti-Oct4 (1:200, Cell Signaling Tech, Danvers, MA), rabbit polyclonal anti-Nanog (1:200, Wako Pure Chemical, Osaka, Japan, wako-chem.co.jp/english), rat monoclonal anti-GFP (1:500, Nacalai Tesque, Kyoto, Japan), rabbit monoclonal anti-Ki67 (1:100, Thermo Fisher Scientific, Grand

Island, New York), rabbit polyclonal anti-active Caspase 3 (1:1000, Cell Signaling Technology, Danvers, MA), mouse monoclonal anti-Nestin (1:200, Rat401, BD Biosciences, San Jose, CA, www.bd.com), mouse monoclonal anti- β III tubulin (1:400, Sigma-Aldrich, St. Louis, MO, www.sigmaaldrich.com), rabbit polyclonal anti-smooth muscle actin (SMA, 1:200, Proteintech, Rosemont, IL), and rabbit polyclonal anti-alpha fetoprotein (AFP, 1:100, Proteintech, Rosemont, IL). Antibodies were detected with Alexa568-conjugated goat anti-rabbit IgG (1:500, Thermo Fisher Scientific, Grand Island, New York); Alexa488-conjugated goat anti-mouse, anti-rabbit, or anti-rat IgG (1:500, Thermo Fisher Scientific, Grand Island, New York); **DyLight 649 donkey anti-rabbit (1:500, BioLegend, San Diego, CA)** and goat anti-mouse IgG-Cy3 (1:500, Jackson ImmunoResearch, West Grove, PA, www.jacksonimmuno.com). Cells were counterstained with DAPI (1 μ g/ml, D523, DOJINDO, Kumamoto, Japan) to visualize nuclei. Fluorescence images were obtained using an AxioImager M1 microscope.

Immunostaining results for cultured cells were quantified by analysing at least two 8-chamber slides. Over 1000 cells were counted from each well, and statistical analyses were performed using Microsoft Excel. Similar results were obtained from three independent experiments, and representative results are shown in each figure.

Vector construction

Full-length mouse *dhodh* cDNA was amplified from mouse NSC cDNA using KOD Plus-Ver.2 polymerase (Toyobo, Osaka, Japan, www.toyobo.co.jp) according to the manufacturer's instructions. These cDNAs were inserted into the p3xFLAG CMV10 vector (Sigma-Aldrich, St. Louis, MO, www.sigmaaldrich.com) to produce p3xFLAG CMV10-mDHODH. The following oligonucleotide DNA primers were synthesized: for

the full-length mouse *dhodh*, the 5' primer was 5'-
AAGAATTCAATGGCGTGGAGACA-3', and the 3' primer was 5'-
TTGGATCCTCACCTGCGGTGATC-3'.

To knock down mouse *dhodh*, three short hairpin (sh) sequences were generated using InvivoGen's siRNA Wizard (<http://www.sirnawizard.com/>). These sh sequences were inserted into a psiRNA-h7SKhygro G1 expression vector (InvivoGen, San Diego, CA, www.invivogen.com) to produce psiRNA-h7SKhygro-mDHODHsh1-3. mDHODHsh expression cassettes were then inserted into pGL3-EGFP vectors to generate pGL3-EGFP-mDHODHsh1-3 (*dhodh sh* expression vectors). The knockdown efficiency of these vectors was analysed by Western blotting and immunostaining (Supporting information Fig. 3). The most efficient vectors *dhodh sh1* and *sh3* were used for the knockdown experiments. The sh1 and sh3 target sequences for mouse *dhodh* were 5'-GGCTAGCTGTTCGAGTCATCT-3' and 5'-GGAAGCTGTGGACGGACTCTA-3', respectively. The control sh target (*egfp*) sequence was 5'-GCAAGCTGACCCTGAAGTTCA-3'.

The nucleotide sequences of the cloned cDNAs were verified using the BigDye Terminator Kit version 3.1 (Thermo Fisher Scientific, Grand Island, New York) and ABI sequencer model 3130xl (Thermo Fisher Scientific, Grand Island, New York). Cells were transfected with the vectors using Lipofectamine 3000 (Thermo Fisher Scientific, Grand Island, New York) according to the manufacturer's protocol.

Teratoma formation

PSCs were cultured in the presence or absence of BRQ for 2 days. The surviving cells (1×10^6) were then suspended in 50 μ l of Matrigel (BD Biosciences, San Jose, CA,

www.bd.com) and injected subcutaneously into the hips of NOD/SCID mice aged 5-8 weeks, which were anaesthetized with 10% pentobarbital before the transplantation procedures. Four weeks after injection, mice were sacrificed, and the tumours were collected, photographed, and measured as described previously.²³

To examine the anti-teratoma activity of BRQ, mice bearing the subcutaneous tumour were intraperitoneally administered 200 µl of PBS or 25 mg/kg BRQ (TOCRIS Bioscience, Bristol, UK) daily in 200 µl of PBS. Five days after BRQ treatment, mice were sacrificed, and the tumours were collected, photographed, and processed for immunostaining as described previously.²³

Statistical analysis

Student's *t* test was used to compare two paired groups. *P* values less than .05 (two-sided) were considered significant.

Results

The DHODH inhibitor BRQ specifically inhibited the proliferation of PSCs

I first examined whether DHODH inhibitors eliminated PSCs. I cultured mouse ESCs and iPSCs in various concentrations of the established DHODH inhibitors teriflunomide, leflunomide, vidofludimus, and BRQ for 3 days and then examined cell viability by the MTT assay. As shown in Fig. 1A, BRQ at less than 25 µM completely prevented the proliferation of ESCs and iPSCs, while other inhibitors produced similar effects at only 200 µM. The half maximal growth inhibitory concentration (GI₅₀) values of BRQ were 4.67 and 6.41 µM for ESCs and iPSCs, respectively. I next investigated the cytotoxicity induced by these DHODH inhibitors in primary cultured brain cells

(NSCs and astrocytes), C2C12 myoblasts, and PA6 stromal cells. None of the inhibitors induced obvious cytotoxicity in NSCs or astrocytes, even at 100 μ M, although BRQ and vidofludimus slightly inhibited the proliferation of C2C12 and PA6 cells in a dose-dependent manner (Fig. 1B and 1C; Supporting information Fig. 1). The GI_{50} of BRQ was 31.5 μ M and 115 μ M for the C2C12 and PA6 cells, respectively. Together, these data indicated that BRQ significantly inhibited the proliferation of PSCs, while it induced low levels of cytotoxicity in proliferating lineage-committed cells.

To verify that BRQ induced cytotoxicity in PSCs by blocking the de novo pyrimidine synthesis pathway, I performed two rescue experiments using uridine, the substrate for the salvage pathway, and uridine diphosphate (UDP), a downstream product of the pyrimidine synthesis pathway (Supporting information Fig. 2A). I cultured ESCs and iPSCs in the presence of BRQ with various concentrations of nucleosides for 3 days and then examined their viability. The addition of uridine abrogated BRQ-induced cytotoxicity in a dose-dependent manner (Fig. 1D). The addition of cytidine slightly reduced the cytotoxicity, whereas the addition of the other nucleosides did not show any effect (Fig. 1D). I then cultured ESCs and iPSCs in the presence of BRQ with various concentrations of nucleotide diphosphates, intermediate substrates for nucleic acid synthesis, and found that UDP addition abrogated the cytotoxicity in a manner similar to uridine, whereas the addition of the other nucleotide diphosphates showed no significant effects (Fig. 1E). Together, these data revealed that BRQ inhibited PSC proliferation by blocking DHODH activity and that the cytotoxicity of BRQ can be eliminated by accelerating the salvage pathway.

BRQ induced cell cycle arrest and cell death in PSCs

To confirm that BRQ induced cell cycle arrest in PSCs, I performed a bromodeoxyuridine (BrdU) incorporation assay. Two days after BRQ treatment, 16% and 14% of the BRQ-treated ESCs and iPSCs, respectively, were positive for BrdU, whereas 30% and 35% of the control ESCs and iPSCs, respectively, were positive for BrdU (Fig. 2A).

Since I observed many floating cells in the BRQ-containing PSC culture, I examined whether BRQ induced the death of PSCs. I cultured PSCs in the presence or absence of BRQ for 2 days and then immunolabeled the cells for cleaved caspase 3 (Casp3). While 8% and 5% of the control ESCs and iPSCs, respectively, were positive for Casp3, 12% and 22% of the BRQ-treated ESCs and iPSCs, respectively, were positive for Casp3 (Fig. 2B; Supporting information Fig. 2A). Using annexin V immunoreactivity, I confirmed that BRQ induced cytotoxicity in PSCs: 58% and 71% of the BRQ-treated ESCs and iPSCs, respectively, were positive for annexin V, whereas 4% of both control ESCs and iPSCs were positive for annexin V (Fig. 2C).

To further verify that BRQ eliminated PSCs, I examined the expression of the core PSC genes *Sox2*, *Oct4* and *Nanog* in BRQ-treated PSCs. Two days after BRQ treatment, I observed decreased expression of these three genes in BRQ-treated cultured cells compared with that in control cells in culture (Fig. 2D). Moreover, immunostaining indicated that the number of cells expressing PSC genes significantly decreased in the BRQ-treated culture, whereas most of the control PSCs were positive for these factors (Supporting information Fig. 2B). Taken together, these data revealed that BRQ eradicated PSCs by inducing cell cycle arrest and cell death in culture.

Using DHODH-specific shRNAs (Supporting information Fig. 3), I examined whether BRQ-dependent cytotoxicity induced in PSCs was dependent on the inhibition

of DHODH activity. Three days after transfection with the *dhodh sh*-expression vectors, I immunolabeled the cells for Ki67 and Casp3. I observed that the number of Ki67+/GFP+ proliferating PSCs significantly decreased, whereas the number of Casp3+/GFP+ dying cells increased (Fig. 3; Supporting information Fig. 4), a finding similar to that observed in the BRQ-treated cells. These data showed that the BRQ-dependent cytotoxicity was induced by inhibition of DHODH activity.

The proliferation/survival of PSCs was largely dependent on the de novo pyrimidine synthesis pathway

I examined why DHODH inhibitors effectively prevent PSC proliferation, despite pyrimidine synthesis being regulated by both the de novo and salvage pathways (Supporting information Fig. 5A). I first examined the expression of *dhodh* and *uridine-cytidine kinases* (*uck1* and *uck2*), key regulators of the salvage pathway,²⁶ in NSCs, ESCs, iPSCs, PA6 cells, and C2C12 cells. Both *dhodh* and *ucks* were highly expressed in ESCs, iPSCs, PA6 cells, and C2C12 cells compared with their expression in NSCs; however, the *dhodh/uck1* ratio was significantly higher in ESCs (2.65) and iPSCs (5.16) than in other cells (1 in NSCs, 0.85 in PA6 cells, and 1.09 in C2C12 cells) (Supporting information Fig. 5B, 5C), suggesting that ESCs and iPSCs depend on the de novo pathway to a greater extent than NSCs, PA6 cells, and C2C12 cells. In addition, the human protein atlas (<https://www.proteinatlas.org>) revealed that the *DHODH/UCK1* ratio in all normal human tissues, except the liver (1.56), is relatively low (less than 0.65) (Supporting information Fig. 5D). The following cancer cell lines have a high *DHODH/UCK1* ratio: K562 (1.35), NB4 (1.77), U937 (1.46), Daudi (1.89), and U698 (2.52) (Supporting information Fig. 5E). These data are consistent with the previous

finding that BRQ prevented tumorigenesis of U937 cells more efficiently than that of THP1 cells (0.8).¹⁵ Furthermore, *ucks*-knockdown PSCs continued to proliferate (Supporting information Fig. 6C), although *dhodh* knockdown induced cell cycle arrest and cell death (Fig. 3; Supporting information Fig. 2A). Eventually, I succeeded in establishing *uck1*- and *uck2*-double knockdown PSCs (Supporting information Fig. 6D). Thus, these findings indicated that PSC proliferation is largely dependent on the de novo pyrimidine synthesis pathway, acting by increasing *dhodh* expression.

BRQ induced the nuclear export of PSC factors in a Crm1-dependent manner

Since it was previously demonstrated that the DHODH inhibitor induced nuclear export of Sox2 in glioblastoma-initiating cells,¹⁸ independent of its cytotoxicity, I examined whether BRQ induces similar phenomena in PSCs. Two days after BRQ treatment, the number of PSCs expressing either Oct4 (2% in the ESCs and 0% in the iPSCs) or Nanog (6% in the ESCs and 0% in the iPSCs) significantly decreased compared with that of DMSO-treated control ESCs (Oct4, 85% and Nanog, 86%) and iPSCs (Oct4, 94% and Nanog, 93%) (Supporting information Fig. 7A, 7B). The addition of the pan-caspase inhibitor Z-VAD did not rescue the reduction in Nanog (2% in the ESCs and 5% in the iPSCs) or Oct4 (5% in the ESCs and 3% in the iPSCs) in the BRQ-treated PSCs, although it slightly delayed BRQ-dependent cell death, suggesting that cell death and the decreased levels of Nanog and Oct4 were independent events in the BRQ-treated cells (Supporting information Fig. 7A, 7B).

Since it was previously shown that leptomycin B (LMB), a specific inhibitor of Crm1, prevented the nuclear export of Sox2 in DHODH inhibitor-treated GICs,¹⁸ I also examined whether the addition of LMB would lead to Nanog and Oct4 retention in the

nuclei of BRQ-treated PSCs. Two days after culturing PSCs with BRQ or BRQ plus LMB, I found that LMB completely blocked the nuclear export of Nanog and Oct4 in the BRQ-treated PSCs (Supporting information Fig. 7C, 7D). Thus, these data indicated that **BRQ excluded Nanog and Oct4 from the nuclei in a Crm1-dependent manner.**

BRQ specifically eliminated PSCs co-cultured with NSCs

The ultimate goal of this study was to demonstrate that BRQ prevents teratoma formation by depleting undifferentiated PSCs that reside with differentiating/differentiated cells in vitro and in vivo. I therefore co-cultured PSCs with NSCs in the presence or absence of BRQ and then examined the specific cytotoxicity induced by BRQ in the PSCs. Three days after the co-culture was seeded, I immunolabeled the cells for Nanog and the NSC marker Nestin. In the cultures with 10 μ M BRQ, no Nanog⁺ cells (red in the ESCs, green in the iPSCs) were detected, although many surviving cells were Nestin⁺ (green in the ESCs, red in the iPSCs) (Fig. 4A, 4B). In contrast, both Nanog⁺ and Nestin⁺ cells were observed in the cultures treated with DMSO alone or 1 μ M BRQ (Fig. 4A, 4B). To quantify the BRQ-dependent specific level of cytotoxicity induced in PSCs, I co-cultured GFP-expressing PSCs with PKH26-labelled NSCs in the presence and absence of 10 μ M BRQ for 3 days and then counted the number of surviving cells. In the absence of BRQ, the numbers of GFP⁺ ESCs and PKH26⁺ NSCs were 170×10^5 cells and 12×10^5 cells, respectively, while those of GFP⁺ iPSCs and PKH26⁺ NSCs were 116×10^5 cells and 13×10^5 cells, respectively. In the presence of BRQ, the number of GFP⁺ ESCs and GFP⁺ iPSCs decreased significantly (5×10^5 cells and 2×10^5 cells, respectively); however, 7×10^5 PKH26⁺ NSCs were detected in both cultures. These data revealed that BRQ killed

more than 97% of the PSCs, whereas approximately 60% of the NSCs survived in the same culture (Fig. 4C, 4D).

I further examined whether BRQ selectively eliminates PSCs from co-cultures with PSC-NSCs. Three days after addition of BRQ, I immunolabeled the cells for Nanog and Nestin. In the presence of 10 μ M BRQ, few Nanog-positive cells were detected in culture, whereas many surviving cells were positive for Nestin (Fig. 4E, 4F, Supporting information Fig. 8C, 8D), confirming the specific elimination of PSCs by BRQ.

BRQ-pretreated PSCs lost tumorigenicity in vivo

I examined the tumorigenicity of BRQ-pretreated PSCs. Two days after culturing the PSCs with DMSO alone or with 10 μ M BRQ, I injected the surviving cells subcutaneously into the hips of NOD/SCID mice. Four weeks after transplantation, the BRQ-pretreated cells did not grow, whereas the DMSO-treated cells formed large tumours (Fig. 5A). The tumour sizes of the DMSO- and BRQ-pretreated PSCs were 0.44 cm³ and 0.07 cm³, respectively, in the ESCs and 0.78 cm³ and 0.05 cm³, respectively, in the iPSCs (Fig. 5B). I then made sections and immunolabeled them for the PSC markers Oct4 and Nanog and for the differentiation markers for the three germ layers Nestin, β III tubulin, ATF, and SMA. Although a large number of Oct4⁺ and Nanog⁺ cells were detected in the DMSO-treated tumours, I observed no Oct4⁺ cells and only a small number of Nanog⁺ cells in BRQ-treated grafts (Fig. 5C, 5D). In contrast, I found differentiated cells expressing markers for the three germ layers in every tumour (Fig. 5C, 5D). Notably, I recognized no sign of tumorigenesis in mice transplanted with

BRQ-pretreated PSCs, even 6 months after transplantation. Together, these data indicated that BRQ pretreatment efficiently prevented tumorigenesis in PSCs in culture.

BRQ administration prevented teratoma formation in vivo

Given that DHODH inhibitors have been shown to prevent tumorigenesis in many types of cancers,¹⁴⁻¹⁸ I examined whether BRQ prevents PSC tumorigenesis. I transplanted PSCs subcutaneously into the hips of NOD/SCID mice and allowed the tumours to reach a size greater than 100 mm³ before initiating intraperitoneal injection of BRQ once every 3 days. Three days after the fifth injection, I removed the tumours from the mice. As shown in Fig. 6A and 6B, BRQ administration strongly prevented tumour growth without any visible side effects in the mice. The sizes of the DMSO- and BRQ-treated teratomas were 0.55 cm³ and 0.12 cm³, respectively, for the ESCs and 1.37 cm³ and 0.32 cm³, respectively, for the iPSCs. I then made sections and immunolabeled them for the proliferation marker Ki67, PSC markers (Oct4 and Nanog), and differentiation markers (ATF, β III tubulin, and SMA). I confirmed that the number of Ki67⁺ proliferating cells was greatly decreased in the BRQ-treated tumours compared with the number in the DMSO-treated tumours (Fig. 6C; Supporting information Fig. 9). I also observed that the number of both Oct4⁺ and Nanog⁺ cells was significantly decreased in the BRQ-treated tumours, whereas the DMSO-treated tumours contained many cells expressing these PSC markers (Fig. 6D, 6E). In contrast, both DMSO- and BRQ-treated tumours similarly contained differentiated cells expressing ATF, β III tubulin, and SMA (Fig. 6D, 6E). Thus, these data revealed that BRQ prevented tumorigenesis by specifically eliminating undifferentiated PSCs in tumours without inducing any obvious cytotoxicity in the differentiated cells and mice.

Discussion

Before proceeding with successful cell therapy using PSCs, it is essential to establish methods that prevent teratoma formation caused by contaminated PSCs. The results of this study demonstrated that the DHODH inhibitor BRQ specifically eliminated PSCs by inducing cell cycle arrest, cell death, and stemness loss without inducing any cytotoxicity in co-cultured NSCs. Moreover, BRQ prevented not only the tumorigenesis of the pretreated PSCs but also the growth of teratomas in vivo, although the PSC-derived differentiated cells were unaffected. It is essential to evaluate whether DHODH inhibitors such as BRQ can be used as essential fundamental agents for PSC-based regenerative medicine using human PSCs, as mouse and human PSCs have been reported to be metabolically different.²⁷

The finding that BRQ specifically eliminated PSCs without inducing any toxicity against NSCs or differentiated cells raised questions regarding the mechanism involved. I found that the *dhodh/uck1* expression ratio in PSCs was significantly higher than that in NSCs and differentiated cells, indicating that PSCs preferentially use the de novo pyrimidine synthesis pathway rather than the salvage pathway. This is consistent with findings that PSCs largely depend on exogenous glutamine, the substrate for the de novo pathway, to maintain their rapid proliferation.^{28,29} Therefore, it is of interest to investigate the molecular mechanisms that increase the *dhodh/uck1* expression ratio in PSCs.

I demonstrated that BRQ induced the Crm1-dependent nuclear export of Nanog and Oct4 in PSCs. DHODH inhibitors have been shown to induce nuclear export of transcription factors, including NF- κ B and Sox2, by preventing the O-GlcNAcylation of these factors,^{18,30} suggesting that the nuclear localization of both Nanog and Oct4 is

regulated by their O-GlcNAcylation and by Crm1. Indeed, Nanog contains the nuclear export signal (NES), a target site of Crm1, and a Eukaryotic Linear Motif (<http://elm.eu.org>) analysis identified a potential NES in Oct4.³¹ O-GlcNAcylation of Oct4 was demonstrated to be essential for the maintenance of ESCs.³² Although Nanog was unlikely to be O-GlcNAcyated, O-GlcNAcyated ESRRB, which regulates the self-renewal and pluripotency of PSCs, has been shown to associate strongly with Nanog and Oct4 and increase their transcriptional activity.^{33,34} These findings suggested that O-GlcNAcylation completely regulates the nuclear localization and activity of core PSC factors. Thus, the detailed mechanism by which O-GlcNAcylation and Crm1 regulate the nuclear localization of PSC factors is an interesting subject for future investigations.

Conclusion

The results of this study demonstrated that BRQ selectively induced cell cycle arrest and cell death in PSCs but was less toxic to non-PSCs. It was also shown that BRQ-pretreated PSCs did not form teratomas, while BRQ administration prevented teratoma growth with the eradication of PSC marker-positive cells in tumours. Thus, these findings revealed that DHODH inhibitors such as BRQ can be used as fundamental chemicals for PSC-based cell therapy.

Acknowledgement

The author thanks Shinji Masui for E14tg2a and a general method for PSC culture, and Hisataka Sabe for C2C12.

Disclosure of potential conflicts of interest

The author indicated no potential conflicts of interests.

References

1. Yamanaka S, Blau HM. Nuclear reprogramming to a pluripotent state by three approaches. *Nature* 2010;465:704-712.
2. Gokhale PJ, Andrews PW. The development of pluripotent stem cells. *Curr Opin Genet Dev* 2012;22:403-408.
3. Cahan P, Daley GQ. Origins and implications of pluripotent stem cell variability and heterogeneity. *Nat Rev Mol Cell Biol* 2013;14:357-368.
4. Avior Y, Sagi I, Benvenisty N. Pluripotent stem cells in disease modelling and drug discovery. *Nat Rev Mol Cell Biol* 2016;17:170-182.
5. Ilic D, Ogilvie C. Concise Review: Human Embryonic Stem Cells-What Have We Done? What Are We Doing? Where Are We Going? *Stem Cells* 2017;35:17-25.
6. Tang C, Lee AS, Volkmer JP, et al. An antibody against SSEA-5 glycan on human pluripotent stem cells enables removal of teratoma-forming cells. *Nat Biotechnol* 2011;29:829-834.
7. Shiraki N, Shiraki Y, Tsuyama T, et al. Methionine metabolism regulates maintenance and differentiation of human pluripotent stem cells. *Cell Metab* 2014;19:780-794.
8. Kuang Y, Miki K, Parr CJC, et al. Efficient, Selective Removal of Human Pluripotent Stem Cells via Ecto-Alkaline Phosphatase-Mediated Aggregation of Synthetic Peptides. *Cell Chem Biol* 2017;24:685-694.
9. Ben-David U, Gan QF, Golan-Lev T, et al. Selective elimination of human pluripotent stem cells by an oleate synthesis inhibitor discovered in a high-throughput screen. *Cell*

Stem Cell 2013;12:167-179.

10. Cliff TS, Dalton S. Metabolic switching and cell fate decisions: implications for pluripotency, reprogramming and development. *Curr Opin Genet Dev* 2017;46:44-49.

11. Tsogtbaatar E, Landin C, Minter-Dykhouse K, et al. C.D.L. Energy Metabolism Regulates Stem Cell Pluripotency. *Front Cell Dev Biol* 2020;8:87.

12. Tohyama S, Fujita J, Hishiki T, et al. Glutamine Oxidation Is Indispensable for Survival of Human Pluripotent Stem Cells. *Cell Metab* 2016;23:663-674.

13. Scalise M, Pochini L, Galluccio M, et al. Glutamine Transport and Mitochondrial Metabolism in Cancer Cell Growth *Front Oncol* 2017;7:306.

14. White RM, Cech J, Ratanasirintrao S, et al. DHODH modulates transcriptional elongation in the neural crest and melanoma. *Nature* 2011;471:518-522.

15. Sykes DB, Kfoury YS, Mercier FE, et al. Inhibition of Dihydroorotate Dehydrogenase Overcomes Differentiation Blockade in Acute Myeloid Leukemia. *Cell* 2016;167:171-186.

16. Brown KK, Spinelli JB, Asara JM, et al. Adaptive Reprogramming of De Novo Pyrimidine Synthesis Is a Metabolic Vulnerability in Triple-Negative Breast Cancer. *Cancer Discov* 2017;7:391-399.

17. Koundinya M, Sudhalter J, Courjaud A, et al. Dependence on the Pyrimidine Biosynthetic Enzyme DHODH Is a Synthetic Lethal Vulnerability in Mutant KRAS-Driven Cancers. *Cell Chem Biol* 2018;25:705-717.

18. Echizenya S, Ishii Y, Kitazawa S, et al. Discovery of a new pyrimidine synthesis inhibitor eradicating glioblastoma-initiating cells. *Neuro-Oncol* 2020;22:229-239.

19. Johe KK, Hazel TG, Muller T, et al. Single factors direct the differentiation of stem

- cells from the fetal and adult central nervous system. *Genes Dev* 1996;10:3129–3140.
20. Hide T, Takezaki T, Nakatani Y, et al. Combination of a pTgs2 inhibitor and an epidermal growth factor receptor-signaling inhibitor prevents tumorigenesis of oligodendrocyte lineage-derived glioma-initiating cells. *Stem Cells* 2011;29:590-599.
21. Kodama HA, Amaga Y, Koyama H, et al. Hormonal responsiveness of a preadipose cell line derived from newborn mouse calvaria. *J Cell Physiol* 1982;112:83-88.
22. Kondo T, Raff M. Chromatin remodeling and histone modification in the conversion of oligodendrocyte precursors to neural stem cells. *Genes Dev* 2004;18:2963–2972.
23. Tsukamoto Y, Ohtsu N, Echizenya S, et al. Chemical Screening Identifies EUrd as a Novel Inhibitor Against Temozolomide-Resistant Glioblastoma-Initiating Cells. *Stem Cells* 2016;34:2016-2025.
24. Kondo T, Raff M. The Id4 HLH protein and the timing of oligodendrocyte differentiation. *EMBO J* 2000;19:1998-2007.
25. Takanaga H, Tsuchida-Straeten N, Nishide K, et al. Gli2 Is A Novel Regulator of Sox2 Expression In Telencephalic Neuroepithelial Cells. *Stem Cells* 2009;27:165–174.
26. Balestri F, Barsotti C, Lutzemberger L, et al. Key role of uridine kinase and uridine phosphorylase in the homeostatic regulation of purine and pyrimidine salvage in brain. *Neurochem Int* 2007;51:517-523.
27. Zhou W, Choi M, Margineautu D, et al. HIF1 α induced switch from bivalent to exclusively glycolytic metabolism during ESC-to-EpiSC/hESC transition. *EMBO J* 2012;31:2103-2116.
28. Ryu JM, Lee SH, Seong JK, et al. Glutamine contributes to maintenance of mouse embryonic stem cell self-renewal through PKC-dependent downregulation of HDAC1 and DNMT1/3a. *Cell Cycle*. 2015;14:3292-3305.

29. Lees JG, Gardner DK, Harvey AJ. Nicotinamide adenine dinucleotide induces a bivalent metabolism and maintains pluripotency in human embryonic stem cells. Stem Cells. 2020;38:624-638.

30. Yang WH, Park SY, Nam HW, et al. NFkappaB activation is associated with its O-GlcNAcylation state under hyperglycemic conditions. Proc Natl Acad Sci USA 2008;105:17345-17350.

31. Park SW, Do HJ, Huh SH, et al. Identification of a putative nuclear export signal motif in human NANOG homeobox domain. Biochem Biophys Res Commun 2012;421:484-489.

32. Jang H, Kim TW, Yoon S, et al. O-GlcNAc regulates pluripotency and reprogramming by directly acting on core components of the pluripotency network. Cell Stem Cell 2012;11:62-74.

33. Speakman CM, Domke TC, Wongpaiboonwattana W, et al. Elevated O-GlcNAc levels activate epigenetically repressed genes and delay mouse ESC differentiation without affecting naïve to primed cell transition. Stem Cells 2014;32:2605-2615.

34. Hao Y, Fan X, Shi Y, et al. Next-generation unnatural monosaccharides reveal that ESRRB O-GlcNAcylation regulates pluripotency of mouse embryonic stem cells. Nat Commun 2019;10:4065.

Figure legends

Figure 1. BRQ specifically eliminates PSCs

(A): Dose-dependent effects of the DHODH inhibitors teriflunomide (diamond), leflunomide (square), vidofludimus (cross), and BRQ (circle) against ESCs (left panel) and iPSCs (right panel). (B): Dose-dependent effects of BRQ against NSCs (closed circle), astrocytes (closed triangle), and ESCs (open circle). (C): Dose-dependent

effects of BRQ against PA6 (closed circle), C2C12 (closed triangle), and ESCs (open circle). **(D)**: Rescue effects of ribonucleosides, uridine (circles), adenosine (diamond), guanosine (square), and cytidine (triangle) against BRQ (10 μ M)-dependent cytotoxicity towards ESCs (left panel) and iPSCs (right panel). **(E)**: Rescue effects of nucleotide diphosphates, UDP (circles), CDP (diamond), ADP (square), and GDP (triangle) against BRQ (10 μ M)-dependent cytotoxicity towards ESCs (left panel) and iPSCs (right panel). All experiments were repeated at least three times with similar results. The error bars indicate $\pm$ SD. A *t* test was used for statistical significance. ** $P < .01$, *** $P < .001$.

Figure 2. BRQ induced cell cycle arrest and cell death in PSCs

(A): Proportion of BrdU⁺ cells among PSCs, ESCs, and iPSCs cultured with DMSO or BRQ (10 μ M) for 2 days. **(B)**: Proportion of CASP3⁺ cells among PSCs, ESCs, and iPSCs cultured with DMSO or BRQ (10 μ M) for 2 days. **(C)**: Proportion of annexin V⁺ cells among PSCs, ESCs, and iPSCs cultured with DMSO or BRQ (10 μ M) for 2 days. **(D)**: Quantitative RT-PCR analysis of the expression of *sox2*, *oct4* and *nanog* in PSCs, ESCs, and iPSCs cultured with DMSO or BRQ (10 μ M) for 2 days. The mRNA levels are shown as fold changes over mRNA levels in the presence of DMSO. All experiments were repeated at least three times with similar results. Error bar: $\pm$ SD. Statistical significance was determined by the *t* test. * $P < .05$, ** $P < .01$, *** $P < .001$.

Figure 3: DHODH knockdown induced cell cycle arrest and cell death in PSCs

(A): Proportion of Ki67⁺ cells among either *control sh-* or *dhodh sh-* expressing ESCs (left panel) and iPSCs (right panel). **(B)**: Proportion of Casp3⁺ cells among either *control*

sh- or *dhodh sh*-expressing ESCs (left panel) and iPSCs (right panel). All experiments were repeated at least three times with similar results. Error bar: $\pm$ SD. Statistical significance was determined by the *t* test. $*P < .05$, $**P < .01$, $***P < .001$.

Figure 4. BRQ selectively eliminated PSCs co-cultured with NSCs

(A, B): Representative immunostained images of co-cultured PSCs, ESCs **(A)** and iPSCs **(B)** with NSCs in the presence of DMSO or BRQ (1 and 10 μ M) for Nestin and Nanog. Scale bar: 100 μ m. **(C, D):** BRQ cytotoxicity against ESCs **(C)**, iPSCs **(D)**, and NSCs. **(E, F):** BRQ cytotoxicity against ESCs **(E)**, iPSCs **(F)**, and PSC-NSCs. Error bar: $\pm$ SD. Statistical significance was determined by the *t* test. $*P < .05$, $**P < .01$, $***P < .001$.

Figure 5. BRQ-pretreated PSCs lost tumorigenicity in vivo

(A): Representative photographs of teratomas formed by ESCs and iPSCs, which were pretreated with DMSO alone or BRQ (10 μ M). Scale bar: 1 cm. **(B):** Size of the teratoma formed by the pretreated ESCs and iPSCs. Statistical significance was determined by the *t* test. Error bar: $\pm$ SD. $***P < .001$. **(C, D):** Representative immunostaining images of teratomas formed by pretreated ESCs **(C)** and iPSCs **(D)** for Oct4 (red), Nanog (green), AFP (green), β III tubulin (red), and SMA (green). Nuclei were counterstained with DAPI (blue). Scale bar: 100 μ m.

Figure 6. BRQ prevented tumour growth of the transplanted PSCs

(A): Representative photographs of teratomas formed by ESCs (left panels) and iPSCs (right panels) in mice treated with DMSO alone or BRQ (25 mg/kg). **(B):** Size of teratomas formed by ESCs and iPSCs in mice treated with DMSO or BRQ. **(C):**

Proportion of Ki67+ cells in teratomas formed by ESCs and iPSCs in mice treated with DMSO or BRQ. **(D, E):** Representative immunostaining images of teratomas formed by ESCs **(D)** and iPSCs **(E)** in mice treated with DMSO or BRQ for Oct4 (red), Nanog (green), AFP (green), β III tubulin (red), and SMA (green). Nuclei were counterstained with DAPI (blue). Scale bar: 100 μ m.

For Peer Review

Figure 1. BRQ specifically eliminates PSCs

Figure 2. BRQ induced cell cycle arrest and cell death in PSCs

118x108mm (300 x 300 DPI)

Figure 3: DHODH knockdown induced cell cycle arrest and cell death in PSCs

113x82mm (300 x 300 DPI)

Figure 5. BRQ-pretreated mPSCs lost tumorigenicity in vivo
154x142mm (300 x 300 DPI)

Figure 6. BRQ prevented tumour growth of the transplanted mPSCs

167x145mm (300 x 300 DPI)

Supplementary Information

Supplementary Methods

Western blotting

Western blotting was performed as previously described²³. In brief, the FLAG-tagged mouse DHODH expression vector was transfected with a *control sh* (cont) or *dhodh sh1-3* expression vector into Cos7 cells. Cell extracts were harvested 2 days after transfection and then analysed by Western blotting using anti-FLAG M2 (10 µg/ml, Sigma-Aldrich, St. Louis, MO, www.sigmaaldrich.com) and anti-GAPDH (loading control, 1:5000, Proteintech, Rosemont, IL) antibodies. Antibodies were detected with horseradish peroxidase-conjugated anti-mouse IgG (1:5000, Santa Cruz Biotechnology Inc., Santa Cruz, CA, <http://www.scbt.com>).

Construction of knockdown vectors for *uck1* and *uck2*

To knock down mouse *uck1* and *uck2*, two short hairpin (sh) sequences of each were generated using InvivoGen's siRNA Wizard (<http://www.sirnawizard.com/>). These sh sequences were inserted into a psiRNA-DUO expression vector (InvivoGen, San Diego, CA, www.invivogen.com) to produce psiRNA-DUO-*muck1 sh1*, -*muck1 sh2*, -*muck2 sh1*, -*muck2 sh2*, and -*muck1 sh1* and -*muck2 sh1*. The knockdown efficiency of these vectors was analysed by immunostaining (Supporting information Fig. 6A, 6B). The target sequences for mouse *uck1* and *uck2* were as follows: *uck1 sh1* and *sh2* were 5'-GAGCCAGGACTGCTTCTACAA-3' and 5'-GGACTGCTTCTACAAGGTTCT-3', respectively, and *uck2 sh1* and *sh2* were 5'-GCCGATGTGATCATTCTCTAGA-3' and 5'-GCAGACGAACGGCTATCTCAA-3', respectively.

The nucleotide sequences were verified using the BigDye Terminator Kit version 3.1 (Thermo Fisher Scientific, Grand Island, New York) and an ABI sequencer model 3130xl (Thermo Fisher Scientific, Grand Island, New York). Cells were transfected with the vectors using Lipofectamine 3000 (Thermo Fisher Scientific, Grand Island, New York) according to the manufacturer's protocol.

To examine the knockdown efficiency of shRNAs, the transfected cells were immunolabeled with rat monoclonal anti-GFP (1:500, Nacalai Tesque) and rabbit polyclonal anti-DHODH (1:100, Proteintech, Rosemont, IL), anti-Uck1 (1:100, Proteintech, Rosemont, IL) or anti-Uck2 (1:100, Proteintech, Rosemont, IL) (Supplementary information Fig. 3B, 3C, 6A, 6B).

The *uck1* and *uck2* double-knockdown PSCs were established by culturing the transfected cells in the presence of zeocin (0.1 mg/ml) for one week (Supplementary information Fig. 6E, 6F).

Supplementary Figure legends

Figure 1. Cytotoxicity of DHODH inhibitors against PA6 and C2C12 cells

Dose-dependent effects of the DHODH inhibitors teriflunomide (diamond), leflunomide (square), vidofludimus (triangle) and BRQ (circle) against PA6 (upper panel) and C2C12 (lower panel) cells.

Figure 2. BRQ increased Casp3 activation in PSCs and decreased PSC marker-positive cells

(A): PSCs were cultured in the presence of DMSO alone or BRQ (10 μ M) for 2 days and then immunostained for cleaved Casp3 (red). (B): PSCs were treated as in (A) and then

immunostained for the PSC markers Sox2, Nanog and Oct4 (green). Arrows indicate PSC marker-negative cells. Nuclei were counterstained with DAPI (blue). Scale bar: 100 μ m.

Figure 3. Knockdown efficiency of *dhodh sh* expression vectors

(A): The FLAG-tagged mouse DHODH expression vector was transfected with a *control sh* (cont) or *dhodh sh1-3* expression vector into Cos7 cells. Cell extracts were harvested 2 days after transfection and then analysed by Western blotting using anti-FLAG and anti-GAPDH (loading control) antibodies. **(B, C):** Representative photographs of either *control sh*-, *dhodh sh1*- or *dhodh sh3*-expressing ESCs **(B)** and iPSCs **(C)** that were immunostained for GFP (green) and DHODH (purple). Arrows indicate GFP+/DHODH-cells. All nuclei were counterstained with DAPI (blue). Scale bar, 100 μ m.

Figure 4. Knockdown of *dhodh* decreased Ki67⁺ cells and increased Casp3⁺ cells in PSCs

(A): Representative photographs of either *control sh*- or *dhodh sh*-expressing PSCs that were immunostained for GFP (green) and Ki67 (red). **(B):** Representative photographs of either *control sh*- or *dhodh sh*-expressing PSCs that were immunostained for GFP (green) and cleaved Casp3 (red). All nuclei were counterstained with DAPI (blue). Scale bar, 100 μ m.

Figure 5. Increased *dhodh/uck1* expression ratio in PSCs

(A): Pyrimidine biosynthesis pathways. **(B):** Quantitative RT-PCR analysis of the expression of *dhodh*, *uck1* and *uck2* in NSCs, ESCs, iPSCs, PA6 cells and C2C12 cells. The mRNA levels are shown as fold changes over mRNA levels in NSCs. **(C):** Ratio of

dhodh/uck1 in NSCs, ESCs, iPSCs, PA6 cells and C2C12 cells. **(D):** Ratio of *DHODH/UCK1* in normal human tissues. **(E):** Ratio of *DHODH/UCK1* in human cell lines. The black dotted line indicates that a ratio of 1.

Figure 6. Effects of *uck1* and *uck2* knockdown in PSCs

(A, B): Representative photographs of either *control sh-*, *uck1 sh-* or *uck2 sh-* expressing ESCs that were immunostained for GFP (green) and either Uck1 (purple) **(A)** or Uck2 (purple) **(B)**. Arrows indicate GFP⁺/Uck⁻ cells. * GFP⁺/Uck2⁺ cells. **(C):** Representative photographs of *control sh-*, *uck1 sh1* or *uck2 sh1*-expressing PSCs, ESCs (left panels) and iPSCs (right panels) that were immunostained for GFP (green) and Ki67 (red). Arrows indicate GFP⁺/Ki67⁺ cells. **(D):** Representative photographs of *control sh-* or *uck1 sh1* and *uck2 sh1*-expressing PSCs, ESCs and iPSCs that were immunostained for GFP (green) and Uck1 (red) (left panels) or GFP (green) and Uck2 (red) (right panels). All nuclei were counterstained with DAPI (blue). Scale bar, 100 μ m.

Figure 7. LMB prevented the BRQ-dependent nuclear export of PSC markers

(A, B): Addition of ZVAD did not prevent BRQ-dependent nuclear export of Oct4 (green) and Nanog (red) in ESCs **(A)** and iPSCs **(B)**. **(C, D):** Addition of LMB retained Oct4 (green) and Nanog (red) in the nucleus of BRQ-treated ESCs **(C)** and iPSCs **(D)**. Nuclear PSC marker⁺ cells are shown as a percentage of the total cells. Nuclei were counterstained with DAPI (blue). Scale bar, 50 μ m in A and 100 μ m in B.

Figure 8. PSC-derived NSC differentiation

(A, B): PSC-derived NSCs, ES-derived NSCs (A) and iPS-derived NSCs (B) were positive for Nestin (green) and Sox2 (red). When the cells were cultured in either mitogen-free NSC medium or DMEM+1% FCS for 1 week, they differentiated into β III tubulin⁺ neurons (green) and GFAP⁺ astrocytes (red) in mitogen-free NSC medium (no mitogen, approximately 29% and 16%, respectively) and in DMEM+1% FCS (approximately 9% and 57%, respectively). Arrows indicate β III tubulin⁺/GFAP⁺ cells. (C, D): Representative immunostained images of co-cultured PSCs, ESCs (C) and iPSCs (D) with PSC-NSCs in the presence of DMSO or BRQ (1 and 10 μ M) for Nestin (green) and Nanog (red). Scale bar, 100 μ m.

Figure 9. BRQ administration decreased Ki67⁺ cells in teratomas

Representative immunostaining images of teratomas that were formed by ESCs and iPSCs in mice treated with DMSO or BRQ for Ki67 (red). All nuclei were counterstained with DAPI (blue). Scale bar, 100 μ m.

Figure legend for Graphical Abstract

This study demonstrated that Brequinar (BRQ), an inhibitor for the dihydroorotate dehydrogenase (DHODH), not only induced cell cycle arrest and cell death in PSCs in vitro but also prevented tumorigenesis by selectively eliminating PSCs in vivo. Given that BRQ was less toxic for non-PSCs, these findings identified DHODH inhibitors, such as BRQ, can be used as fundamental chemicals for PSC-based cell therapy.

● BRQ ▲ Vidofludimus ■ Leflunomide ◆ Teriflunomide

Supplementary Figure 1. Cytotoxicity of DHODH inhibitors against PA6 and C2C12 cells

128x110mm (270 x 270 DPI)

Supplementary Figure 2. BRQ increased Casp3 activation in PSCs and decreased PSC markerpositive cells

120x204mm (270 x 270 DPI)

Supplementary Figure 3. Knockdown efficiency of dhodh sh expression vectors

108x213mm (270 x 270 DPI)

Supplementary Figure 4. Knockdown of dhodh decreased Ki67+ cells and increased Casp3 + cells in PSCs

132x248mm (270 x 270 DPI)

Supplementary Figure 5. Increased *dhodh* /*uck1* expression ratio in PSCs

180x230mm (270 x 270 DPI)

Supplementary Figure 6. Effects of uck1 and uck2 knockdown in PSCs

176x240mm (270 x 270 DPI)

Supplementary Figure 7. LMB prevented the BRQ-dependent nuclear export of PSC markers

158x166mm (270 x 270 DPI)

Supplementary Figure 8. PSC-derived NSC differentiation

187x165mm (270 x 270 DPI)

Supplementary Figure 9. BRQ administration decreased Ki67 + cells in teratomas

126x105mm (270 x 270 DPI)

This study demonstrated that Brequinar (BRQ), an inhibitor for the dihydroorotate dehydrogenase (DHODH), not only induced cell cycle arrest and cell death in PSCs in vitro but also prevented tumorigenesis by selectively eliminating PSCs in vivo. Given that BRQ was less toxic for non-PSCs, these findings identified DHODH inhibitors, such as BRQ, can be used as fundamental chemicals for PSC-based cell therapy.

102x95mm (254 x 254 DPI)